


administering to said animal an effective amount of a pipecolic acid derivative compound, wherein the nerve-related vision disorder is selected from the group consisting of visual impairments; orbital disorders; disorders of the lacrimal apparatus; disorders of the eyelids; disorders of the conjunctiva; disorders of the cornea; cataract; disorders of the uveal tract; disorders of the retina; disorders of the optic nerve or visual pathways; free radical induced eye disorders and diseases; immunologically-mediated eye disorders and diseases; eye injuries; and symptoms and complications of eye disease, eye disorder, and eye injury, and wherein said compound is selected from the group consisting of



wherein n is 1, 2, or 3;

4 - (4 - methoxyphenyl)butyl (2S) - 1 - [2 - (3, 4, 5 - trimethoxyphenyl)acetyl]hexahydro-2-pyridinecarboxylate;


4 - (4 - methoxyphenyl)butyl (2S) - 1 - [2 - (3, 4, 5 - trimethoxyphenyl)acryloyl]hexahydro-2-pyridinecarboxylate;

4 - (4-methoxyphenyl)butyl (2S)-1-[2-(3,4,5-

trimethoxyphenyl)propanoyl]hexahydro-2-pyridinecarboxylate;

4 - (4-methoxyphenyl)butyl (2S)-1-[2-oxo-2-(3,4,5-

trimethoxyphenyl)acetyl]hexahydro-2-pyridinecarboxylate;



3-cyclohexylpropyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)hexahydro-2-

pyridinecarboxylate;

3-phenylpropyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)hexahydro-2-

pyridinecarboxylate;

3-(3,4,5-trimethoxyphenyl)propyl (2S)-1-(3,3-dimethyl-2-

oxopentanoyl)hexahydro-2-pyridinecarboxylate;

(1R)-2,2-dimethyl-1-phenethyl-3-butenyl (2S)-1-(3,3-dimethyl-2-

oxopentanoyl)hexahydro-2-pyridinecarboxylate;

(1R)-1,3-diphenylpropyl (2S)-1-(3,3-dimethyl-2-

oxopentanoyl)hexahydro-2-pyridinecarboxylate;

(1R)-1-cyclohexyl-3-phenylpropyl (2S)-1-(3,3-dimethyl-2-

oxopentanoyl)hexahydro-2-pyridinecarboxylate;

(1S)-1,3-diphenylpropyl (2S)-1-(3,3-dimethyl-2-

oxopentanoyl)hexahydro-2-pyridinecarboxylate;

(1S)-1-cyclohexyl-3-phenylpropyl (2S)-1-(3,3-dimethyl-2-


oxopentanoyl)hexahydro-2-pyridinecarboxylate;

(22aS)-15,15-dimethylperhydropyrido[2,1-

c][1,9,4]dioxazacyclononadecine-1,12,16,17-tetraone;

(24aS)-17,17-dimethylperhydropyrido[2,1-

c][1,9,4]dioxazacycloheicosine-1,14,18,19-tetraone;



(3R,4R,23aS)-8-allyl-4,10-dimethyl-3-[2-(3-pyridyl)ethyl]-1,3,4,5,6,7,8,11,12,15,16,17,18,20,21,22,23,23a-octadecahydro-14H-


pyrido[2,1-c][1,10,4]dioxazacycloicosine-1,7,14,17,18-pentaone;

(3R,4R,24aS)-8-allyl-4,10-dimethyl-3-[2-(3-pyridyl)ethyl]-1,3,4,5,6,7,8,11,12,14,15,16,17,18,19,21,22,23, 24,24a-


icosahydropyrido[2,1-c][1,11,4]dioxazacycloheicosine-1,7,14,18,19-pentaone;

(3R,4R,25aS)-8-allyl-4,10-dimethyl-3-[2-(3-pyridyl)ethyl]-


1,3,4,5,6,7,8,11,12,15,16,17,18,19,20,22,23, 24,25,25a-icosahydro-  
14H-pyrido[2,1-c] [1,12,4]dioxazacyclodocosine-1,7,14,19,20-  
pentaone;



(b) cont  
wherein n is 1; 2; or 3;



T,1331  
wherein n is 1; 2; or 3;




*X, 1340*

*B cont*

(1R)-1-(3-benzoylphenyl)-3-phenylpropyl (1R)-2-(3,3-dimethyl-2-oxopentanoyl)cyclohexane-1-carboxylate;

(1R)-1-[3-(diallylcarbamoyl)phenyl]-3-phenylpropyl;

(1R)-2-(3,3-dimethyl-2-oxopentanoyl)cyclohexane-1-carboxylate;



*X, 1341*

ethyl 1-(2-oxo-3-phenylpropanoyl)-2-piperidinecarboxylate;

ethyl 1-pyruvyl-2-piperidinecarboxylate;

*134*

*B*

ethyl 1-(2-oxobutanoyl)-2-piperidinecarboxylate;

ethyl 1-(3-methyl-2-oxobutanoyl)-2-piperidinecarboxylate;

ethyl 1-(4-methyl-2-oxopentanoyl)-2-piperidinecarboxylate;

ethyl 1-(3,3-dimethyl-2-oxobutanoyl)-2-piperidinecarboxylate;

ethyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;

4-[2-(ethyloxycarbonyl)piperidinol-2,2-dimethyl-3,4-dioxobutyl

acetate;

ethyl 1-[2-(2-hydroxytetrahydro-2H-2-pyranyl)-2-oxoacetyl]-2-  
piperidinecarboxylate;

ethyl 1-[2-(2-methoxytetrahydro-2H-2-pyranyl)-2-oxoacetyl]-2-  
piperidinecarboxylate;

ethyl 1-[2-(1-hydroxycyclohexyl)-2-oxoacetyl]-2-  
piperidinecarboxylate;

ethyl 1-[2-(1-methoxycyclohexyl)-2-oxoacetyl]-2-  
piperidinecarboxylate;

ethyl 1-(2-cyclohexyl-2-oxoacetyl)-2-piperidinecarboxylate;

ethyl 1-(2-oxo-2-piperidinoacetyl)-2-piperidinecarboxylate;

ethyl 1-[2-(3,4-dihydro-2H-6-pyranyl)-2-oxoacetyl]-2-  
piperidinecarboxylate;

ethyl 1-(2-oxo-2-phenylacetyl)-2-piperidinecarboxylate;

ethyl 1-(4-methyl-2-oxo-1-thioxopentyl)-2-piperidinecarboxylate;

3-phenylpropyl 1-(2-hydroxy-3,3-dimethylpentanoyl)-2-  
piperidinecarboxylate;

(1R)-1-phenyl-3-(3,4,5-trimethoxyphenyl)propyl 1-(3,3-  
dimethylbutanoyl)-2-piperidinecarboxylate;

(1R)-1,3-diphenylpropyl 1-(benzylsulfonyl)-2-piperidinecarboxylate;  
3-(3,4,5-trimethoxyphenyl)propyl 1-(benzylsulfonyl)-2-  
piperidinecarboxylate;

1-(2-[2R,3R,6S]-6-[2S,3E,5E,7E,9S,11R]-2,13-dimethoxy-3,9,11-  
trimethyl-12-oxo-3,5,7-tridecatrienyl]-2-hydroxy-3-  
methyltetrahydro-2H-2-pyranyl)-2-oxoacetyl)-2-piperidinecarboxylic  
acid;

methyl 1-(2-[2R,3R,6S]-6-[2S,3E,5E,7E,9S,11R]-2,13-dimethoxy-  
3,9,11-trimethyl-12-oxo-3,5,7-tridecatrienyl]-2-hydroxy-3-  
methyltetrahydro-2H-2-pyranyl)-2-oxoacetyl)-2-  
piperidinecarboxylate;

isopropyl 1-(2-[2R,3R,6S]-6-[2S,3E,5E,7E,9S,11R]-2,13-dimethoxy-  
3,9,11-trimethyl-12-oxo-3,5,7-tridecatrienyl]-2-hydroxy-3-  
methyltetrahydro-2H-2-pyranyl)-2-oxoacetyl)-2-  
piperidinecarboxylate;

benzyl 1-(2-[2R,3R,6S]-6-[2S,3E,5E,7E,9S,11R]-2,13-dimethoxy-  
3,9,11-trimethyl-12-oxo-3,5,7-tridecatrienyl]-2-hydroxy-3-  
methyltetrahydro-2H-2-pyranyl)-2-oxoacetyl)-2-  
piperidinecarboxylate;

1-phenylethyl 1-(2-[2R,3R,6S]-6-[2S,3E,5E,7E,9S,11R]-2,13-  
dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-tridecatrienyl]-2-hydroxy-  
3-methyltetrahydro-2H-2-pyranyl)-2-oxoacetyl)-2-  
piperidinecarboxylate;


(Z)-3-phenyl-2-propenyl 1-(2-[2R,3R,6S]-6-[2S,3E,5E,7E,9S,11R]-  
2,13-dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-tridecatrienyl]-2-

hydroxy-3-methyltetrahydro-2H-2-pyranyl)-2-oxoacetyl)-2-piperidinecarboxylate;




3-(3,4-dimethoxyphenyl)propyl 1-(2-[<sup>(2R,3R,6S)-6-</sup>  
[<sup>(2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-</sup>  
tridecatrienyl]-2-hydroxy-3-methyltetrahydro-2H-2-pyranyl)-2-  
oxoacetyl)-2-piperidinecarboxylate;

N2-benzyl-1-(2-[<sup>(2R,3R,6S)-6-[<sup>(2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-</sup>  
3,9,11-trimethyl-12-oxo-3,5,7-tridecatrienyl]-2-hydroxy-3-</sup>  
methyltetrahydro-2H-2-pyranyl)-2-oxoacetyl)-2-  
piperidinecarboxylate;




N2-(3-phenylpropyl)-1-(2-[<sup>(2R,3R,6S)-6-[<sup>(2S,3E,5E,7E,9S,11R)-2,13-</sup>  
dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-tridecatrienyl]-2-hydroxy-</sup>  
3-methyltetrahydro-2H-2-pyranyl)-2-oxoacetyl)-2-  
piperidinecarboxylate;




wherein R is methyl (Me); or benzyl (Bn);



wherein n = 2,

orand $R_2 = \text{Phe-}o\text{-tert-butyl};$ wherein $R_1 = m\text{-OCH}_2\text{Ph};$  $R_1 = m\text{-OCH}_2\text{Ph};$  $R_1 = m\text{-OCH}_2\text{Ph};$  $R_1 = m\text{-OCH}_2\text{Ph};$ butyl; $R_1 = m\text{-OCH}_2\text{Ph};$ butyl; $R_1 = B\text{-naphthyl};$  $R_3 = \text{Val-}o\text{-tert-butyl};$  $R_3 = \text{Leu-}o\text{-tert-butyl};$  $R_3 = \text{Ileu-}o\text{-tert-butyl};$  $R_3 = \text{hexahydro-Phe-}o\text{-tert-}$  $R_3 = \text{allylalanine-}o\text{-tert-}$  $R_3 = \text{Val-}o\text{-tert-butyl};$




wherein

R<sub>1</sub> = CH<sub>2</sub>(CO)-m-OCH<sub>3</sub>Ph  
R<sub>4</sub> = CH<sub>2</sub>Ph  
R<sub>5</sub> = OCH<sub>3</sub>;

or

R<sub>1</sub> = CH<sub>2</sub>(CO)-B-naphthyl  
R<sub>4</sub> = CH<sub>2</sub>Ph  
R<sub>5</sub> = OCH<sub>3</sub>;



wherein

R<sub>1</sub> = m-OCH<sub>3</sub>Ph  
X = trans-CH=CH  
R<sub>4</sub> = H  
Y = OC(○)Ph;

R<sub>1</sub> = OCH<sub>3</sub>Ph  
X = trans-CH=CH  
R<sub>4</sub> = H  
Y = OC(○)CF<sub>3</sub>;

R<sub>1</sub> = m-OCH<sub>3</sub>Ph

X = trans-CH=CHI

R<sub>4</sub> = -

Y = -i-

R<sub>1</sub> = m-OCH<sub>3</sub>, Ph

X = trans-CH=CH

R<sub>4</sub> = H


Y = OCH<sub>2</sub>CH=CH<sub>2</sub>i-


R<sub>1</sub> = m-OCH<sub>3</sub>, Ph

X = C=O

R<sub>4</sub> = H

Y = Ph;





*(b) cont'd* wherein

R<sub>1</sub> = H,      R<sub>2</sub> = OMe, and      R<sub>3</sub> = CH<sub>2</sub>OMe;  
R<sub>1</sub> = H,      R<sub>2</sub> = H, and      R<sub>3</sub> = H;  
R<sub>1</sub> = Me,      R<sub>2</sub> = H, and      R<sub>3</sub> = H;

(E)-3-(3,4-dichlorophenyl)-2-propenyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;  
(E)-3-(3,4,5-trimethoxyphenyl)-2-propenyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;  
(E)-3-phenyl-2-propenyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;  
(E)-3-((3-(2,5-dimethoxy)-phenylpropyl)phenyl)-2-propenyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;  
4-(4-methoxyphenyl)butyl 1-(2-oxo-2-phenylacetyl)-2-piperidinecarboxylate;  
3-phenylpropyl 1-(2-oxo-2-phenylacetyl)-2-piperidinecarboxylate;  
3-(3-pyridyl)propyl 1-(2-oxo-2-phenylacetyl)-2-piperidinecarboxylate;  
3-(3-pyridyl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;

4-phenyl-1-(3-phenylpropyl)butyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;

4-(4-methoxyphenyl)butyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;

1-(4-methoxyphenethyl)-4-phenylbutyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;

3-(2,5-dimethoxyphenyl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;

3-(1,3-benzodioxol-5-yl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;

1-phenethyl-3-phenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;

4-(4-methoxyphenyl)butyl 1-(2-cyclohexyl-2-oxoacetyl)-2-piperidinecarboxylate;

3-cyclohexylpropyl 1-(2-cyclohexyl-2-oxoacetyl)-2-piperidinecarboxylate;

3-phenylpropyl 1-(2-cyclohexyl-2-oxoacetyl)-2-piperidinecarboxylate;

3-cyclohexylpropyl 1-(3,3-dimethyl-2-oxobutanoyl)-2-piperidinecarboxylate;

3-phenylpropyl 1-(3,3-dimethyl-2-oxobutanoyl)-2-piperidinecarboxylate;

4-(4-methoxyphenyl)butyl 1-(3,3-dimethyl-2-oxobutanoyl)-2-piperidinecarboxylate; and

4-phenyl-1-(3-phenylpropyl)butyl 1-(3,3-dimethyl-2-oxobutanoyl)-2-piperidinecarboxylate; and

pharmaceutically acceptable salts, esters, and solvates thereof.

26. (Twice Amended) [The method of claim 1, wherein the compound is] A method for treating a nerve-related vision disorder, improving vision, treating memory impairment, or enhancing memory performance in an animal, which comprises administering to said

animal an effective amount of Way-124,666, wherein the nerve-related vision disorder is selected from the group consisting of visual impairments; orbital disorders; disorders of the lacrimal apparatus; disorders of the eyelids; disorders of the conjunctiva; disorders of the cornea; cataract; disorders of the uveal tract; disorders of the retina; disorders of the optic nerve or visual pathways; free radical induced eye disorders and diseases; immunologically-mediated eye disorders and diseases; eye injuries; and symptoms and complications of eye disease, eye disorder, and eye injury.

*3.* (Twice Amended) [The method of claim 1, wherein the compound is] A method for treating a nerve-related vision disorder, improving vision, treating memory impairment, or enhancing memory performance in an animal, which comprises administering to said animal an effective amount of rapamycin, wherein the nerve-related vision disorder is selected from the group consisting of visual impairments; orbital disorders; disorders of the lacrimal apparatus; disorders of the eyelids; disorders of the conjunctiva; disorders of the cornea; cataract; disorders of the uveal tract; disorders of the retina; disorders of the optic nerve or visual pathways; free radical induced eye disorders and diseases; immunologically-mediated eye disorders and diseases; eye injuries; and symptoms and complications of eye disease, eye disorder, and eye injury.

*4.* (Twice Amended) [The method of claim 1, wherein the compound is] A method for treating a nerve-related vision disorder, improving vision, treating memory impairment, or enhancing memory performance in an animal, which comprises administering to said animal an effective amount of Rap-Pa, wherein the nerve-related vision disorder is selected from the group consisting of visual impairments; orbital disorders; disorders of the lacrimal

apparatus; disorders of the eyelids; disorders of the conjunctiva;  
disorders of the cornea; cataract; disorders of the uveal tract;  
disorders of the retina; disorders of the optic nerve or visual  
pathways; free radical induced eye disorders and diseases;  
immunologically-mediated eye disorders and diseases; eye injuries;  
and symptoms and complications of eye disease, eye disorder, and  
eye injury.

*51* 6. (Twice Amended) [The method of claim 1, wherein the compound is] A method for treating a nerve-related vision disorder, improving vision, treating memory impairment, or enhancing memory performance in an animal, which comprises administering to said animal an effective amount of SLE-506, wherein the nerve-related vision disorder is selected from the group consisting of visual impairments; orbital disorders; disorders of the lacrimal apparatus; disorders of the eyelids; disorders of the conjunctiva; disorders of the cornea; cataract; disorders of the uveal tract; disorders of the retina; disorders of the optic nerve or visual pathways; free radical induced eye disorders and diseases; immunologically-mediated eye disorders and diseases; eye injuries; and symptoms and complications of eye disease, eye disorder, and eye injury.

*C* *buf P3* Please add the following new claims:

*-921* 7. The method of claim *91*, wherein the nerve-related vision disorder is retinal ischemia.

*10* 8. The method of claim *91*, wherein the retinal ischemia is selected from the group consisting of degeneration of retinal ganglion cells, degeneration of optic nerve axons, degeneration of myelin sheaths, ischemic optic neuropathy, and retinal vascular blockage.

*11* 9. The method of claim *91*, wherein the nerve-related vision disorder is optic nerve transection.

12. The method of claim 29, wherein the optic nerve transection is selected from the group consisting of ganglion cell death after optic nerve transection and myelin degeneration after optic nerve transection.

C [ ] 13. The method of claim 1, wherein the nerve-related vision disorder is diabetes.

C [ ] 14. The method of claim 31, wherein the diabetes is selected from the group consisting of diabetes from degeneration and diabetic retinopathy.

C [ ] 15. The method of claim 1, wherein the nerve-related vision disorder is macular degeneration.

C [ ] 16. The method of claim 1, wherein the nerve-related vision disorder is glaucoma related degeneration.

C [ ] 17. The method of claim 1, wherein the nerve-related vision disorder is cataract related degeneration.

C [ ] 18. The method of claim 1, wherein the nerve-related vision disorder is a detached retina.

B3 C [ ] 19. The method of claim 1, wherein the nerve-related vision disorder is inflammation related degeneration.

C [ ] 20. The method of claim 1, wherein the nerve-related vision disorder is photoreceptor degeneration.

C [ ] 21. The method of claim 1, wherein the nerve-related vision disorder is optic neuritis.

C [ ] 22. The method of claim 1, wherein the nerve-related vision disorder is dry eye degeneration.

C [ ] 23. The method of claim 1, wherein the nerve-related vision disorder is retinal ischemia.

C [ ] 24. The method of claim 41, wherein the retinal ischemia is selected from the group consisting of degeneration of retinal ganglion cells, degeneration of optic nerve axons, degeneration of myelin sheaths, ischemic optic neuropathy, and retinal vascular blockage.

25. The method of claim 8, wherein the nerve-related vision disorder is optic nerve transection.

26. The method of claim 25, wherein the optic nerve transection is selected from the group consisting of ganglion cell death after optic nerve transection and myelin degeneration after optic nerve transection.

27. The method of claim 8, wherein the nerve-related vision disorder is diabetes.

28. The method of claim 27, wherein the diabetes is selected from the group consisting of diabetes from degeneration and diabetic retinopathy.

29. The method of claim 8, wherein the nerve-related vision disorder is macular degeneration.

30. The method of claim 29, wherein the nerve-related vision disorder is glaucoma related degeneration.

31. The method of claim 8, wherein the nerve-related vision disorder is cataract related degeneration.

32. The method of claim 8, wherein the nerve-related vision disorder is a detached retina.

33. The method of claim 8, wherein the nerve-related vision disorder is inflammation related degeneration.

34. The method of claim 8, wherein the nerve-related vision disorder is photoreceptor degeneration.

35. The method of claim 8, wherein the nerve-related vision disorder is optic neuritis.

36. The method of claim 8, wherein the nerve-related vision disorder is dry eye degeneration.

37. The method of claim 8, wherein the nerve-related vision disorder is retinal ischemia.

38. The method of claim 37, wherein the retinal ischemia is selected from the group consisting of degeneration of retinal ganglion cells, degeneration of optic nerve axons, degeneration of myelin sheaths, ischemic optic neuropathy, and retinal vascular blockage.

*39*  
39. The method of claim 31, wherein the nerve-related vision disorder is optic nerve transection.

*40*  
40. The method of claim 39, wherein the optic nerve transection is selected from the group consisting of ganglion cell death after optic nerve transection and myelin degeneration after optic nerve transection.

*41*  
41. The method of claim 31, wherein the nerve-related vision disorder is diabetes.

*42*  
42. The method of claim 39, wherein the diabetes is selected from the group consisting of diabetes from degeneration and diabetic retinopathy.

*43*  
43. The method of claim 31, wherein the nerve-related vision disorder is macular degeneration.

*44*  
44. The method of claim 31, wherein the nerve-related vision disorder is glaucoma related degeneration.

*45*  
45. The method of claim 31, wherein the nerve-related vision disorder is cataract related degeneration.

*46*  
46. The method of claim 31, wherein the nerve-related vision disorder is a detached retina.

*47*  
47. The method of claim 31, wherein the nerve-related vision disorder is inflammation related degeneration.

*48*  
48. The method of claim 31, wherein the nerve-related vision disorder is photoreceptor degeneration.

*49*  
49. The method of claim 31, wherein the nerve-related vision disorder is optic neuritis.

*50*  
50. The method of claim 31, wherein the nerve-related vision disorder is dry eye degeneration.

*51*  
51. The method of claim 31, wherein the nerve-related vision disorder is retinal ischemia.

*52*  
52. The method of claim 51, wherein the retinal ischemia is selected from the group consisting of degeneration of retinal ganglion cells, degeneration of optic nerve axons, degeneration of myelin sheaths, ischemic optic neuropathy, and retinal vascular blockage.

53 4.1  
51. The method of claim 8, wherein the nerve-related vision disorder is optic nerve transection.

52 53  
52. The method of claim 51, wherein the optic nerve transection is selected from the group consisting of ganglion cell death after optic nerve transection and myelin degeneration after optic nerve transection.

53 4.  
53. The method of claim 8, wherein the nerve-related vision disorder is diabetes.

54 55  
54. The method of claim 53, wherein the diabetes is selected from the group consisting of diabetes from degeneration and diabetic retinopathy.

55 4.  
55. The method of claim 8, wherein the nerve-related vision disorder is macular degeneration.

56 4.  
56. The method of claim 8, wherein the nerve-related vision disorder is glaucoma related degeneration.

57 4.  
57. The method of claim 8, wherein the nerve-related vision disorder is cataract related degeneration.

58 4.  
58. The method of claim 8, wherein the nerve-related vision disorder is a detached retina.

59 4.  
59. The method of claim 8, wherein the nerve-related vision disorder is inflammation related degeneration.

60 4.  
60. The method of claim 8, wherein the nerve-related vision disorder is photoreceptor degeneration.

61 4.  
61. The method of claim 8, wherein the nerve-related vision disorder is optic neuritis.

62 4.  
62. The method of claim 8, wherein the nerve-related vision disorder is dry eye degeneration.

63 4.  
63. The method of claim 8, wherein the nerve-related vision disorder is retinal ischemia.

64 65  
64. The method of claim 8, wherein the retinal ischemia is selected from the group consisting of degeneration of retinal ganglion cells, degeneration of optic nerve axons, degeneration of myelin sheaths, ischemic optic neuropathy, and retinal vascular blockage.

Attorney Docket: 22789-XS  
Serial No.: 09/134,417

*67* 85. The method of claim *8*, wherein the nerve-related vision disorder is optic nerve transection.

*68* 86. The method of claim *85*, wherein the optic nerve transection is selected from the group consisting of ganglion cell death after optic nerve transection and myelin degeneration after optic nerve transection.

*69 67* 87. The method of claim *8*, wherein the nerve-related vision disorder is diabetes.

*70* 88. The method of claim *81*, wherein the diabetes is selected from the group consisting of diabetes from degeneration and diabetic retinopathy.

*71* 89. The method of claim *8*, wherein the nerve-related vision disorder is macular degeneration.

*72* 90. The method of claim *8*, wherein the nerve-related vision disorder is glaucoma related degeneration.

*73* 91. The method of claim *8*, wherein the nerve-related vision disorder is cataract related degeneration.

*74* 92. The method of claim *8*, wherein the nerve-related vision disorder is a detached retina.

*75* 93. The method of claim *8*, wherein the nerve-related vision disorder is inflammation related degeneration.

*76* 94. The method of claim *8*, wherein the nerve-related vision disorder is photoreceptor degeneration.

*77* 95. The method of claim *8*, wherein the nerve-related vision disorder is optic neuritis.

*78* 96. The method of claim *8*, wherein the nerve-related vision disorder is dry eye degeneration.

REMARKS

Upon entry of the above amendments, claims 1, 6-9, 21, 23-24, and 27-96 are pending in the application. The amendments do not add any new matter under 35 U.S.C. §132. Basis for the term